IPO - Medirom Healthcare Technologies Inc.

Back to List of IPO Filings

Form Type: CORRESP

Filing Date: 2024-12-09

Corporate Action: Ipo

Type: New

Accession Number: 000110465924126653

Filing Summary: Medirom Healthcare Technologies Inc. requests acceleration of the effectiveness of its Registration Statement on Form F-1 (File No. 333-281771) to 5:30 p.m. Eastern Time on December 9, 2024. The company indicated that confirmation of this acceleration request should be communicated orally to their counsel, Kenji Taneda of Skadden, Arps, Slate, Meagher & Flom LLP. The request is supported by the representative of the underwriters of the upcoming offering, who joined in a separate letter to the SEC.

Document Link: View Document

Additional details:

Registration Statement: Form F-1


Filing Type: CORRESP


Contact Person: Kenji Taneda


Contact Phone: +81-3-3568-2640


Request Time: 5:30 p.m. Eastern Time


Law Firm: Skadden, Arps, Slate, Meagher & Flom LLP


Ceo Name: Kouji Eguchi


Cfo Name: Fumitoshi Fujiwara


Legal Manager Name: Rumiko Yoneyama


Form Type: CORRESP

Filing Date: 2024-12-09

Corporate Action: Ipo

Type: New

Accession Number: 000110465924126654

Filing Summary: Medirom Healthcare Technologies Inc. has requested the acceleration of the effective date of its Registration Statement on Form F-1, filed as File No. 333-281771. ThinkEquity LLC, acting as the representative of the underwriters of the offering, has formally requested that the Registration Statement become effective on December 9, 2024, at 5:30 p.m. ET, or as soon thereafter as feasible. Additionally, on behalf of the underwriters, ThinkEquity notified the SEC regarding the distribution of the Preliminary Prospectus dated December 4, 2024, indicating compliance with the relevant SEC rules.

Document Link: View Document

Additional details:

Registration Statement File No: 333-281771


Preliminary Prospectus Date: 2024-12-04


Underwriter Representative: ThinkEquity LLC


Request Timestamp: 2024-12-09T17:30:00ET


Comments

No comments yet. Be the first to comment!